Skip to search formSkip to main contentSkip to account menu

MK 2461

Known as: MK-2461, MK2461, c-Met Inhibitor MK2461 
A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor MK2461 preferentially… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Stellate Cells
Objectives Platelet-derived growth factor receptor beta (PDGFR&bgr;) and hepatocyte growth factor receptor (MET) expressed on… 
2015
2015
Abstract 404: MK2461 suppress progression of pancreatic cancer disrupting interaction between pancreatic cancer cells and stellate cells
Pancreatic cancer is characterized excessive desmoplasia, which occupies 80% of pancreatic cancer tissue and mainly consists of… 
2014
2014
MK2461 has efficacy in NCI-H716 xenografts.
2011
2011
Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.
c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer… 
2011
2011
Abstract A40: A novel cMET pharmacodynamic assay using human hair follicles.
The Receptor Tyrosine Kinase cMET is an oncogenic driver of gastric and lung cancer. Clinical development of cMET inhibitors to… 
Highly Cited
2010
Highly Cited
2010
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
The receptor tyrosine kinase c-Met is an attractive target for therapeutic blockade in cancer. Here, we describe MK-2461, a novel… 
2010
2010
Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma
Abstract 4078 Background: Cytokine stimulated signaling pathways contribute to multiple myeloma (MM) disease progression and in… 
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Alemtuzumab, Amlodipine, Anakinra, Azacitidine; Bazedoxifene acetate, Belinostat, Bevacizumab, BI-201335, BI-2536… 
2008
2008
First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors
14657 Background: MK-2461 is a potent small molecule inhibitor of c-Met, a receptor tyrosine kinase involved in tumor cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)